CPT code 0266U: Transcriptome profiling, expression and splicing changes2026 Medicare lab fee · Clinical Laboratory Fee Schedule
Whole-transcriptome next-generation sequencing assesses tissue-specific expression and splicing changes when clinicians investigate unexplained constitutional or other heritable disorders.
Medicare pays $3,200.00 for 0266U under the 2026 Clinical Laboratory Fee Schedule: one national amount, the same in every state and setting.
Medicare lab fee · CLFS 2026 Q4
National CLFS amount
$3,200.00
In effect since Jan 1, 2026. The same amount in every state, payment locality and setting.
- Geographic adjustment
- None
- Office vs facility
- Same
- Since 2023
- Unchanged
- CMS updates
- Quarterly
Medicare pays the lesser of the lab’s charge and this amount. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.
On this page 8 sections
What 0266U covers
This proprietary laboratory analysis uses whole-transcriptome next-generation sequencing to assess tissue-specific gene expression in unexplained constitutional or other heritable disorders. It reports whether splicing or expression changes are present or absent. The clinical question is whether transcript-level changes are detectable in the tested tissue as part of evaluating an unexplained heritable condition. Specimens may include blood, formalin-fixed paraffin-embedded tissue, or fresh frozen tissue.
Report 0266U for this profiling assay. Medicare pays the code through the CLFS at one national amount that applies across states and localities, without geographic adjustment or an office-versus-facility difference. The 2026 national CLFS amount is $3,200, unchanged from 2023 through 2025. Payment is through the CLFS only.
This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.
How Medicare pays 0266U
Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.
One national amount
CMS sets a single Clinical Laboratory Fee Schedule amount for 0266U. There’s no geographic (GPCI) adjustment, so it pays the same in every state and payment locality.
No office or facility rate
Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.
Updated every quarter
CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.
Not on the physician fee schedule
The physician fee schedule doesn’t list 0266U: Medicare pays the test only from the CLFS.
0266U on the lab fee schedule since 2021
0266U · CLFS 2026 Q4 (current)
$3,200.00
Unchanged since Jan 1, 2023
Every change on file
- Jan 1, 2023 · CLFS 2023 Q1MAC-priced → $3,200.00
21 quarterly CLFS releases on file, first CLFS 2021 Q4. A code missing from a quarter wasn’t on that release.
0266U compared with similar tests
- 0265UGenome sequencingRare heritable disorders$5,475.80
- 0266U assesses tissue-specific expression and splicing changes from whole-transcriptome sequencing. 0265U is the rare-disease whole-genome and mitochondrial DNA analysis.
- 0267UGenome testMapping plus sequencing$6,739.33
- 0267U uses optical genome mapping with sequencing for rare-disease identification. Choose 0266U when the ordered test is whole-transcriptome expression and splicing profiling.
- 0268UaHUS genetic test15-gene sequence analysis$608.17
- 0268U is a 15-gene sequencing analysis for atypical hemolytic uremic syndrome. 0266U addresses unexplained heritable disorders through transcriptome expression and splicing analysis.
0266U billing questions
When is 0266U a better fit than a rare-disease genome test?
Use 0266U when the ordered analysis evaluates tissue-specific gene expression or splicing changes by whole-transcriptome sequencing. Genome mapping or broader DNA analysis codes describe different testing methods.
Which specimens can be used for this assay?
The assay may be performed on blood, formalin-fixed paraffin-embedded tissue, or fresh frozen tissue.
What does the result report?
The result reports whether splicing or expression changes are present or absent.
How does Medicare pay 0266U?
Medicare pays it under the CLFS at one national amount across localities, without an office or facility difference.
How does 0266U differ from 0267U?
0266U evaluates tissue-specific expression and splicing by whole-transcriptome sequencing. 0267U uses optical genome mapping and sequencing for rare-disease identification.
Where this amount comes from
FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.
CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027
Show the CMS file line behind this amount
Fee sheets · Coming soon
Put 0266U and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist